This page is the main website for information pertaining to OMUFA reauthorization activities, including high level meeting minutes with industry while negotiations are ongoing.
Similar Posts
Overview & Basics
Generic medicine facts, questions and answers, and FDA review and approval process.Electronic Homecare Bed Correction: Medline Updates Use Instructions for Homecare Beds
Medline updates use instructions for Electronic Homecare Beds due to risk of electrical fires and entrapment.Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic ActSearch for Regulatory References | Drugs
Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and moreFDA In Brief: FDA seeks input on development and evaluation of abuse-deterrent formulations of central nervous system stimulants
FDA seeks input on development and evaluation of abuse-deterrent formulations of central nervous system stimulantsPharmcore Inc. dba Hallandale Pharmacy. Fort Lauderdale, FL. 483 issued 06/13/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/13/2025
Short Title (70 char) Pharmcore Inc. dba Hallandale Pharmacy. Fort Lauderdale, FL. 483 issued 06/13/2025
FEI Number 3014480778
Firm Name Pharmcore Inc. dba Hallandale Pharmacy
Record Type 483
State FL